PROSTVAC® is Bavarian Nordic’s targeted immunotherapy candidate that is being investigated for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Encouraging results from the PROSTVAC development program have led to the initiation of the ongoing pivotal Phase 3 PROSPECT trial, which is being conducted in collaboration with the National Cancer Institute and under a Special Protocol Assessment from the FDA. Data to date also suggest that PROSTVAC holds promise in combination with other therapies and/or in earlier stages of the disease.

PROSTVAC is being studied to see if it has the potential to extend the lives of men with mCRPC, who have limited treatment options. It is our hypothesis that  because it is a targeted immunotherapy with a favorable safety profile, it  may do so with  less of an impact on quality of life. PROSTVAC employs the company’s poxvirus-based (vaccinia-fowlpox-TRICOM) technology platform and targets prostate specific antigen (PSA) in order to induce a specific, direct immune response that attacks cancerous cells in the prostate.

PROSTVAC intended to be ready to use and does not require individual patient blood cell collection, making a simple production and distribution process possible. PROSTVAC is administered subcutaneously, which provides ease of use to physicians and patients.